Halozyme Therapeutics (HALO) Operating Income Growth (1y) (2011 - 2026)
Halozyme Therapeutics (HALO) Operating Income Growth (1y) (2011 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Op. Inc Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
814,307.08 Bn |
814,307.05 Bn |
- |
- |
| 2 |
Belite Bio |
55,320.00 Bn |
55,320.00 Bn |
- |
100.00% |
| 3 |
Quantum Biopharma |
17,149.72 Bn |
17,149.72 Bn |
- |
12.69% |
| 4 |
Legend Biotech |
3,590.00 Bn |
3,589.71 Bn |
242.10 Mn |
75.16% |
| 5 |
Akari Therapeutics |
1,650.72 Bn |
1,650.72 Bn |
- |
-347.04% |
| 6 |
Evaxion A |
1,522.09 Bn |
1,522.07 Bn |
- |
1.27% |
| 7 |
Psyence Biomedical |
229.39 Bn |
229.38 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.09 Bn |
105.85 Bn |
2.59 Bn |
80.62% |
| 9 |
Abivax |
90.15 Bn |
90.15 Bn |
- |
- |
| 10 |
Halozyme Therapeutics |
8.24 Bn |
7.92 Bn |
297.47 Mn |
30.37% |
| Date | Value |
|---|
| Mar 31, 2026 |
30.37% |
| Dec 31, 2025 |
-152.93% |
| Sep 30, 2025 |
33.53% |
| Jun 30, 2025 |
72.68% |
| Mar 31, 2025 |
48.14% |
| Dec 31, 2024 |
73.70% |
| Sep 30, 2024 |
84.87% |
| Jun 30, 2024 |
24.11% |
| Mar 31, 2024 |
77.58% |
| Dec 31, 2023 |
35.60% |
| Sep 30, 2023 |
5.99% |
| Jun 30, 2023 |
177.33% |
| Mar 31, 2023 |
-28.90% |
| Dec 31, 2022 |
31.80% |
| Sep 30, 2022 |
10.20% |
| Jun 30, 2022 |
-63.39% |
| Mar 31, 2022 |
49.15% |
| Dec 31, 2021 |
-27.17% |
| Sep 30, 2021 |
87.56% |
| Jun 30, 2021 |
214.83% |
